The US FDA has posted details, including company and FDA Briefing Materials, for the Monday, October 20, 2014 meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC). The committee will review the biologics license application (BLA) 125504, secukinumab, a human monoclonal antibody, submitted by Novartis, proposed for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

See the SAC Tracker Report